Recently established improvement of epigenetic therapy by combination with the BCL-2 inhibitor venetoclax or targeted therapy in IDH1 or IDH2 mutated AML offers reasonable therapeutic option with a significantly lower risk of severe complications as compared to intensive chemotherapy regimens (DiNardo et al. 2020; Roboz et al. 2020; Pollyea et al. 2019). The gene discussed is IDH2; the disease is acute myeloid leukemia.